MARKET

ROIVW

Roivant Sciences
ROIVW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-5.0977
41.17
2.316
-
Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million
PUBT · 1d ago
Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum
Simply Wall St · 2d ago
Roivant Sciences price target raised to $40 from $35 at JPMorgan
TipRanks · 4d ago
Roivant Sciences Is Maintained at Buy by Guggenheim
Dow Jones · 5d ago
Roivant Sciences Price Target Raised to $36.00/Share From $30.00 by Guggenheim
Dow Jones · 5d ago
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $36
Benzinga · 5d ago
Roivant Sciences price target raised to $36 from $30 at Guggenheim
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB)
TipRanks · 5d ago
More

Webull offers Roivant Sciences stock information, including NASDAQ: ROIVW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ROIVW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ROIVW stock methods without spending real money on the virtual paper trading platform.